{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:30:48Z","timestamp":1783524648831,"version":"3.55.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The clinical data of patients with double-positive for leucine-rich glioma-inactivated protein 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) antibodies is limited, particularly for children. This study aimed to investigate and summarize the clinical features and long-term prognosis of children\u2019s LGI1 and CASPR2 antibodies related to neurological disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We collected the clinical data and prognosis of patients with dual positive antibodies of CASPR2 and LGI1, hospitalized in the Department of Neurology, Children\u2019s Hospital of Chongqing Medical University. Furthermore, we summarized the clinical phenotypes of this disorder in children by reviewing the published literature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two patients presenting with variable neurological symptoms including pain, hypertension, profuse sweating, irritability, and dyssomnia from Children\u2019s Hospital of Chongqing Medical University were enrolled in this study. Together with the two patients, we identified 17 children with dual CASPR2 and LGI1 antibodies, including 12 males and 5 females. At the onset, the median age was 4.1 years (range 1\u201316, interquartile range 2.5\u201313.5), with 9 children younger than 5 years and 6 adolescents. Of the 17 patients, 11 were diagnosed with Morvan syndrome, 4 with acquired neuromyotonia, 1 with Guillain-Barr\u00e9 syndrome, and 1 with Guillain-Barr\u00e9 syndrome combined with Morvan syndrome. Dysautonomia (14\/17, 82.3%), pain (13\/17, 76.4%), sleep disorders (13\/17, 76.4%), encephalopathy (12\/17, 70.5%), and weight loss (10\/17, 58.8%) were the most frequently described symptoms overall. No tumors were identified. Of the 17 patients, 13 received immunotherapy comprising IVIG combination of IVMP during the acute symptomatic phase followed by oral prednisolone to maintain remission (<jats:italic>n<\/jats:italic> = 7), the combination of IVIG, IVMP, oral prednisolone and methotrexate (<jats:italic>n<\/jats:italic> = 1), the combination of IVIG, IVMP, and mycophenolate mofetil (<jats:italic>n<\/jats:italic> = 1), the combination of IVIG, IVMP, oral prednisolone, and rituximab (<jats:italic>n<\/jats:italic> = 1), IVIG only (<jats:italic>n<\/jats:italic> = 2), IVMP only (<jats:italic>n<\/jats:italic> = 1). Median modified Rankin Scale (mRS) scores in the acute phase were 3 (range 1\u20134) and improved gradually. Over the follow-up (median 8.6 months, range 1\u201336 months), 52.9% (9\/17) of the patients recovered completely; one patient relapsed and showed immunotherapy-dependent.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>LGI1 and CASPR2 double-positive antibodies associated with the neurological diseases can occur in children of all ages and involve multiple nervous systems. Morvan syndrome is the most common phenotype of this disorder. The long-term outcomes are mostly favorable upon immunotherapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.815976","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T04:45:44Z","timestamp":1649306744000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Phenotypic Spectrum of CASPR2 and LGI1 Antibodies Associated Neurological Disorders in Children"],"prefix":"10.3389","volume":"10","author":[{"given":"Yan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengbing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingsong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxiong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/WCO.0000000000000444","article-title":"Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies).","volume":"30","author":"Bastiaansen","year":"2017","journal-title":"Curr Opin Neurol."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.10618","article-title":"Clinical characteristics of patients double positive for CASPR2 and LGI1-antibodies.","volume":"197","author":"Jia","year":"2020","journal-title":"Clin Neurol Neurosurg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1212\/WNL.0000000000003173","article-title":"Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up.","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00415-019-09686-2","article-title":"Systematic review of the clinical spectrum of CASPR2 antibody syndrome.","volume":"267","author":"Boyko","year":"2020","journal-title":"J Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/ana.25310","article-title":"LGI1 and CASPR2 neurological autoimmunity in children.","volume":"84","author":"Lopez-Chiriboga","year":"2018","journal-title":"Ann Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e2290","DOI":"10.1212\/WNL.0000000000009523","article-title":"CASPR2 autoimmunity in children expanding to mild encephalopathy with hypertension.","volume":"94","author":"Syrbe","year":"2020","journal-title":"Neurology."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.736035","article-title":"Clinical features and outcomes in pediatric autoimmune encephalitis associated with CASPR2 antibody.","volume":"9","author":"Tan","year":"2021","journal-title":"Front Pediatr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1212\/WNL.0000000000002917","article-title":"The clinical spectrum of Caspr2 antibody-associated disease.","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/dmcn.14179","article-title":"Acquired neuromyotonia in children with CASPR2 and LGI1 antibodies.","volume":"61","author":"Surana","year":"2019","journal-title":"Dev Med Child Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ana.23577","article-title":"Morvan syndrome: clinical and serological observations in 29 cases.","volume":"72","author":"Irani","year":"2012","journal-title":"Ann Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 syndrome.","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577008","article-title":"LGI1 and CASPR2 autoimmunity in children: systematic literature review and report of a young girl with Morvan syndrome.","volume":"335","author":"Nosadini","year":"2019","journal-title":"J Neuroimmunol."},{"key":"B13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1212\/WNL.0000000000004861","article-title":"Morvan syndrome associated with CASPR2 and LGI1 antibodies in a child.","volume":"90","author":"Nikolaus","year":"2018","journal-title":"Neurology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/jns.12089","article-title":"Guillain-Barr\u00e9 syndrome associated with CASPR2 antibodies: two paediatric cases.","volume":"19","author":"Rosch","year":"2014","journal-title":"J Peripher Nerv Syst."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1007\/s00415-021-10614-6","article-title":"Pediatric LGI1 and CASPR2 autoimmunity associated with COVID 19: morvan syndrome.","volume":"268","author":"Kilic","year":"2021","journal-title":"J Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ana.26189","article-title":"Leucine-rich glioma-inactivated 1 versus contactin-associated protein-like 2 antibody neuropathic pain: clinical and biological comparisons.","volume":"90","author":"Ramanathan","year":"2021","journal-title":"Ann Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1093\/brain\/awq213","article-title":"Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan\u2019s syndrome and acquired neuromyotonia.","volume":"133","author":"Irani","year":"2010","journal-title":"Brain."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1111\/ejn.14081","article-title":"Contactin-associated protein-like 2, a protein of the neurexin family involved in several human diseases.","volume":"48","author":"Saint-Martin","year":"2018","journal-title":"Eur J Neurosci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/jnnp-2017-315720","article-title":"LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes.","volume":"89","author":"Binks","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ana.24979","article-title":"Expanded phenotypes and outcomes among 256 LGI1\/CASPR2-IgG-positive patients.","volume":"82","author":"Gadoth","year":"2017","journal-title":"Ann Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/jamaneurol.2018.2681","article-title":"Association of leucine-rich glioma inactivated protein 1, contactin-associated protein 2, and contactin 2 antibodies with clinical features and patient-reported pain in acquired neuromyotonia.","volume":"75","author":"Vincent","year":"2018","journal-title":"JAMA Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1001\/jamaneurol.2013.2863","article-title":"Acquired neuromyotonia heralding recurrent thymoma in myasthenia gravis.","volume":"70","author":"Fleisher","year":"2013","journal-title":"JAMA Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.4103\/1673-5374.215268","article-title":"Structure and function of the contactin-associated protein family in myelinated axons and their relationship with nerve diseases.","volume":"12","author":"Zou","year":"2017","journal-title":"Neural Regen Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/practneurol-2020-002567","article-title":"Autoimmune encephalitis: clinical spectrum and management.","volume":"21","author":"Uy","year":"2021","journal-title":"Pract Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","article-title":"Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management.","volume":"92","author":"Abboud","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s40674-018-0089-z","article-title":"An update on the treatment of pediatric autoimmune encephalitis.","volume":"4","author":"Stingl","year":"2018","journal-title":"Curr Treatm Opt Rheumatol."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.815976\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T04:45:47Z","timestamp":1649306747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.815976\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":26,"alternative-id":["10.3389\/fped.2022.815976"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.815976","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]},"article-number":"815976"}}